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ABSTRACT
SUMOylation is recently found to function as a targeting
signal for the degradation of substrates through the
ubiquitin-proteasome system. RNF4 is the most studied
human SUMO-targeted ubiquitin E3 ligase. However, the
relationship between SUMO proteases, SENPs, and RNF4
remains obscure. There are limited examples of the SENP
regulation of SUMO2/3-targeted proteolysis mediated by
RNF4. The present study investigated the role of SENP3 in
the global protein turnover related to SUMO2/3-targeted
ubiquitination and focused in particular on the SENP3
regulation of the stability of Sp1. Our data demonstrated
that SENP3 impaired the global ubiquitination proﬁle and
promoted the accumulation of many proteins. Sp1, a
cancer-associated transcription factor, was among these
proteins. SENP3 increased the level of Sp1 protein via
antagonizing the SUMO2/3-targeted ubiquitination and the
consequent proteasome-dependent degradation that was
mediated by RNF4. De-conjugation of SUMO2/3 by SENP3
attenuated the interaction of Sp1 with RNF4. In gastric
cancer cell lines and specimens derived from patients and
nude mice, the level of Sp1 was generally increased in
parallel to the level of SENP3. These results provided a
new explanation for the enrichment of the Sp1 protein in
various cancers, and revealed a regulation of SUMO2/3
conjugated proteins whose levels may be tightly con-
trolled by SENP3 and RNF4.
KEYWORDS SUMOylation, ubiquitination, SENP3,
RNF4, Sp1, gastric cancer
INTRODUCTION
Ubiquitin and the small ubiquitin-like modiﬁer (SUMO) all
belong to a type of small post-translational protein modiﬁers
(Gill, 2004; Herrmann et al., 2007; Yeh et al., 2000). An
increasing number of proteins have been identiﬁed as the
substrates of both modiﬁers (Hunter and Sun, 2008; Ulrich,
2005). SUMOylation and ubiquitination occur on the same
protein and even at the same lysine residue. They may lead
to opposite consequences in protein stability because
SUMOylation competes with ubiquitination and antagonizes
ubiquitin-proteasome-mediated degradation (Denuc and
Marfany, 2010; Ulrich, 2005). However, a novel class of
ubiquitin ligases termed “SUMO-targeted ubiquitin ligases
(STUbL)” has been discovered in recent years, and the
related human RNF4 homodimer is among the best descri-
bed STUbL (Abed et al., 2011; Geoffroy and Hay, 2009;
Sriramachandran and Dohmen, 2014). Thus, SUMOylation
can target proteins for degradation through the ubiquitin-
proteasome system (Schimmel et al., 2008). Ubiquitination
modiﬁes the substrates that have been precedently
SUMOylated, during which STUbLs add ubiquitin directly at
the SUMO chain moieties or other lysine sites of the sub-
strates (Geoffroy and Hay, 2009). This SUMO-targeted
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proteolysis is important for a variety of cellular processes
(Praefcke et al., 2012).
The SUMO family in humans primarily includes SUMO1,
SUMO2 and SUMO3 (Bossis and Melchior, 2006; Yeh et al.,
2000). SUMO2 and SUMO3 are 96% similar to each other
and are thus called SUMO2/3 (Geiss-Friedlander and Mel-
chior, 2007; Yeh et al., 2000). SUMO1 and SUMO2/3 are
conjugated to substrates through an enzymatic cascade
(Bernier-Villamor et al., 2002; Bossis and Melchior, 2006;
Sampson et al., 2001). The conjugation of SUMO to an
internal lysine (K) residue of another SUMO can lead to the
formation of substrate-attached SUMO chains (poly-
SUMOylation) (Bylebyl et al., 2003; Tatham et al., 2001). It
has been believed that SUMO2/3 form SUMO chains more
effectively than SUMO1 (Matic et al., 2008). SUMOylation
can be reversed, i.e., single SUMO moieties or SUMO
chains can be de-conjugated, by a family of SUMO pro-
teases or SENPs in mammals (Drag and Salvesen, 2008).
The SENPs family consists of SENP1–SENP3 and SENP5–
SENP7, where SENP3, -5, -6 and -7 have preferences for
SUMO2/3 de-conjugation (Gong and Yeh, 2006) and SENP6
and SENP7 have speciﬁcity for SUMO chains (Lima and
Reverter, 2008).
Therefore, the STUbLs and SUMO proteases can both
affect the dynamics and consequences of SUMOylation
(Sun et al., 2007). The connection between these two types
of enzymes has been recently demonstrated (Mukhopad-
hyay et al., 2010; Wang et al., 2006). However, the rela-
tionship between the SUMO proteases and the STUbLs
remains largely obscure. For example, SUMO proteases
are assumed to de-SUMOylate STUbLs’ substrates des-
tined for the proteasome before or after the substrates’
arrival at the proteasome (Hickey et al., 2012); however,
the SUMO proteases can de-SUMOylate the substrates at
the very beginning of the process, i.e., before they become
the substrates of the STUbLs (Mukhopadhyay et al., 2010).
The moment when SENPs perform de-SUMOylation, i.e.,
before or after the conjugation of ubiquitin by STUbLs,
needs to be clariﬁed. Although the list of substrates for
mammalian STUbL RNF4 has grown rapidly in recent years
(Sriramachandran and Dohmen, 2014) and novel STUbL,
Arkadia (RNF111), has been discovered (Erker et al., 2013;
Poulsen et al., 2013), there are limited examples of the
SENP regulation of SUMO-targeted proteolysis mediated
by mammalian STUbL (Mukhopadhyay et al., 2010). Most
of the STUbLs bear multiple SUMO interaction motifs
(SIMs) that mediate cooperative binding to multiple SUMO
units, thereby providing a preference for substrates with
SUMO chains (Tatham et al., 2008; Uzunova et al., 2007).
Thus, the STUbls have a preference of substrates conju-
gated with SUMO2/3 that form SUMO chains more effec-
tively than with SUMO1 (Matic et al., 2008). RNF4 is shown
to act in a SUMO2/3-dependent manner (Sriramachandran
and Dohmen, 2014). However, among the SUMO2/3
speciﬁc proteases, only SENP6 is reported to stabilize its
substrate by antagonizing RNF4 (Mukhopadhyay et al.,
2010). It is not clear whether other SUMO2/3 speciﬁc
SENPs are involved in the STUbL-mediated protein ubiq-
uitination/degradation.
Speciﬁcity protein 1 (Sp1) is a ubiquitously expressed
basal transcription factor that regulates a large panel of
target genes (Wang et al., 2003). Increased Sp1 accumu-
lation and transcriptional activity have been found in various
cancerous tissues and cell lines (Honda et al., 2006; Kanai
et al., 2006; Lou et al., 2005). Sp1 is regulated by multiple
types of post-translational modiﬁcations (PTM) (Chang and
Hung, 2012). Previous research has suggested that the
SUMO1 conjugation of Sp1 facilitates the interaction
between Sp1 and the subunit of proteasome rpt6, resulting in
RNF4-dependent ubiquitin-proteasomal degradation (Wang
et al., 2008). A recent work has showed that SUMO1 and
SUMO2/3 can differentially regulate the role of Sp1 (Gong
et al., 2014). Thus, we wondered whether Sp1 can be con-
jugated with SUMO2/3 and be a substrate of SENP3, as we
have previously shown that the protein level of SENP3, a
Figure 1. SENP3 impairs the global ubiquitination
proﬁle. (A) HEK293T (293T) cells were transfected with
RH-SUMO3, HA-Ubiquitin (HA-Ub) and GFP-SENP3 for
48 h. The ubiquitin and SUMO3 conjugations of global
proteins were determined by immunoblotting (IB) using the
antibodies against the tags. (B) 293T cells were trans-
fected with HA-Ubiquitin (HA-Ub) and the increased doses
of GFP-SENP3 for 48 h. The ubiquitin and endogenous
SUMO2/3 conjugations of global proteins were determined
by IB using the antibodies against the tags and SUMO2/3.
(C) 293T cells were transfected with GFP-SENP3 or GFP
vector, or transfected with SENP3 siRNA or non-speciﬁc
(NS) siRNA for 48 h. The endogenous ubiquitin and
SUMO2/3 conjugations of global proteins were determined
by IB using the indicated antibodies. (D) 293T cells were
transfected with SENP3 or vector for 48 h. The cell lysates
were run through 10% SDS-PAGE and the gel was silver
stained. The increased proteins at major band of approx-
imately 100 kDa (arrowhead) were examined by mass
spectrometry (MS). 293Tcells were transfected with vector
FLAG-pcDNA or FLAG-SENP3 and Co-IP was performed
using anti-FLAG antibody. The gel was silver stained and
the proteins of interest at bands of approximately 100 kDa
(braces) were examined by MS. (E) The proteins identiﬁed
by MS were classiﬁed into the nuclear or cytoplasmic
proteins and cancer-associated or non-associated proteins
by a bioimformatic analysis based on the data banks
(Subcellular localization analysis: Gene Ontology (Cellular
Component) annotation with DAVID; and Cancer gene
exploration: COSMIC database (Version 68) of Sanger),
further classiﬁed into known or unknown MG132-sensitive
SUMO targets based on literatures. (F) 293T cells were
transfected with FLAG-pcDNA or FLAG-SENP3 for 48 h,
then transfected cells were lysed for Co-IP with M2 beads
and detected by Cullin1, Cullin2, Cullin3 (abbreviated as
CUL1,2,3), XRCC5 (Ku80) and Ku70 antibodies.
s
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SUMO2/3 speciﬁc protease, is increased in tumor tissues
and under various stress conditions (Han et al., 2010; Huang
et al., 2009; Yan et al., 2010).
The present study investigated the role of SENP3 in the
global protein turnover related to SUMO2/3-targeted ubiq-
uitination, and focused in particular on the SENP3 regula-
tion of the stability of Sp1. Our ﬁndings provide a new
explanation for the enrichment of Sp1 protein in cancers
and suggest a global regulation of SUMO2/3 conjugated
proteins whose levels may be tightly controlled by SENP3
and RNF4.
RESULTS
SENP3 impairs the global ubiquitination proﬁle
We tested whether SENP3, a SUMO2/3-speciﬁc protease,
could affect global ubiquitination. HEK293T cells were co-
transfected with ubiquitin (Ub), SUMO3 and SENP3, respec-
tively or in combination. Immunoblotting of whole cell lysates
showed that global ubiquitin conjugations, in particular those
at higher molecular weight, were dramatically increased when
SUMO3 was overexpressed (Fig. 1A, compare lane 5 with
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SUMO3 decreased the global SUMO3 conjugations and
concomitantly decreased the global ubiquitin conjugations
(Fig. 1A, compare lane 3 with lane 2, and lane 6 with lane 5).
Furthermore, the overexpression of an increasing dose of
SENP3 in cells that expressed exogenous ubiquitin and
endogenous SUMO2/3 led to a marked decrease of ubiquitin
conjugations in a SENP3 dose-dependent pattern (Fig. 1B).
We then further determined endogenous SUMO2/3 and
ubiquitin conjugations in cells with SENP3 overexpression
and knockdown. A parallel decrease or increase of SUMO2/3
and ubiquitin conjugations could be observed in these two
pairs of cells (Fig. 1C).
The data indicated that the ubiquitination of a population of
proteins relies on SUMO3 conjugation, and the de-conjugation
of SUMO3 by SENP3 can attenuate ubiquitination. Thus, we
wanted to identify proteins that were prevented by SENP3
from undergoing ubiquitin/proteasome-mediated degradation
and became stabilized. SENP3 was overexpressed in 293T
cells, and the cell lysates were run through electrophoresis.
Silver staining showed an enrichment of proteins in the posi-
tion of 100 kDa and above in SENP3-transfected cells, com-
pared to those in vector-transfected cells (Fig. 1D, left). We
took the major band of approximately 100 kDa and examined it
with mass spectrometry. Remarkably, the levels of 268 pro-
teins were plausibly increased by SENP3. To search the
proteins that were increased through interaction with SENP3,
no matter directly or indirectly, we co-immunoprecipitated
proteins using the tagged SENP3 and analyzed the bands of
approximately 100 kDa by mass spectrometry (Fig. 1D, right).
The results showed 360 proteins that had direct or indirect
interaction with SENP3. Sixty-six proteins that overlapped in
these two groups were then considered to be increased
through the possible interaction with SENP3 (Table 1).
SENP3, as a nucleolar protein, preferentially, neverthe-
less not exclusively, interacts with nuclear proteins (Drag
and Salvesen, 2008; Gong and Yeh, 2006; Han et al., 2010;
Hickey et al., 2012; Huang et al., 2009; Mukhopadhyay and
Dasso, 2007; Yan et al., 2010), and has increased levels in
various cancer tissues (Han et al., 2010; Hickey et al., 2012).
Therefore, these proteins were examined by a bioinformatic
analysis based on the databases (Gene Ontology Cellular
Table 1. The proteins interacting with SENP3 and probably being increased by SENP3
Nuclear UBE3A, XAB2, KPNB1, MCM4, NUP93, CDC5L, ELAC2, GTF3C4, NCBP1, TELO2, MAD1L1, MCM3,
DHX15, DDX27, CUL1, UBTF, VCP, ZW10, TRIM28, MATR3, NSUN2, CUL3, HNRNPUL1, RRP1B,
LAS1L, ZC3H14, XRCC5, MCM5, NCAPH, MCM7, SSRP1, SP1, MRE11A, DDX17
Cytoplasmic PSMD2, COPG1, COPG2, PYGL, PYGB, GANAB, DRIP4, PDCD6IP, EEF2, HSP90B1, TRA1, MOGS,
GCS1, VPS35, AP1G1, UFL1, RRM1, CSDE1, SEC63, QARS, ALDH18A1, MAGED1, PFKP, TFRC,







Figure 2. SENP3 regulates the Sp1 protein level
through interfering with the SUMO2/3-targeted ubiqui-
tin/proteasome pathway. (A) 293T cells were transfected
with the increasing doses of GFP-SENP3 for 48 h or the
oligonucleotides for SENP3 siRNA for 72 h. Sp1 protein
levels were determined by IB using the antibody against
Sp1. Global SUMO2/3 conjugation was detected by IB with
antibody against SUMO2/3. STAT3, as a negative control,
was also detected by IB with its antibody (upper). Sp1
mRNA levels were determined by qRT-PCR at the same
time (bottom). (B) 293T cells were transfected with RH-
SUMO3 or pcDNA3 and then were exposed to the protein
synthesis inhibitor cycloheximide (CHX) for indicated time.
Sp1 protein levels were determined by IB using the
antibody against Sp1. Global SUMO2/3 conjugation was
detected by IB (upper). The Sp1 levels were normalized to
the actin levels at each time point, being quantiﬁed by
intensity analysis with ImageJ software. The relative Sp1
levels were calculated and displayed in two ways. The Sp1
level in the mock-transfected cells at the 0 h of CHX
treatment was taken as 100%, and those at each time
point in the mock-transfected cells and SUMO3-express-
ing cells were compared (bottom left). Alternatively, the
Sp1 levels in the mock-transfected cells and SUMO3-
expressing cells at the zero time point of CHX treatment
were taken as 100% respectively, and those at each time
point were compared with their own beginning levels,
showing the differences when Sp1 level in the SUMO3-
expressing cells reached to 50% of its beginning level
(right plot). *, P < 0.05. (C) 293Tcells were transfected with
RH-SUMO3 for 48 h in the presence/absence of MG132
(10 μmol/L) for the last 10 h. Sp1 protein levels were
determined by IB using the antibody against Sp1. Global
SUMO2/3 conjugation was detected by IB. (D) 293T cells
were transfected with RH-SENP3 or vector for 48 h. The
Sp1 interactions with exogenous SENP3 were determined
by immunoprecipitation (IP) using anti-Sp1 and anti-RH
antibodies respectively and IB as indicated. (E) Co-IP
using anti-Sp1 antibody or IgG were performed in 293T
cells with or without H2O2 exposure, and precipitation of
endogenous SENP3 was determined by IB with anti-
SENP3 antibody.
s
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Component annotation with DAVID, and Cancer gene
exploration COSMIC database Version 68) of Sanger (For-
bes et al., 2011; Huang da et al., 2009; Keshava Prasad
et al., 2009; Shepherd et al., 2011) and classiﬁed into sub-
types according to whether they were nuclear proteins and
known cancer-associated proteins (Fig. 1E, left and middle).
Moreover, we searched for those that had been reported in
literature (Gong et al., 2014; Schimmel et al., 2008; Wang
et al., 2008) to be stabilized by the proteasome inhibitor
MG132 and simultaneously modiﬁed by SUMO. Surprisingly,
only a few were known to be regulated by SUMO-targeted
ubiquitination (Fig. 1E, right). We further performed co-im-
munoprecipitation (co-IP) assays using available antibodies
to corroborate whether the listed nuclear proteins indeed had
physical interaction with SENP3. Cullin family members,
CUL1 and CUL3, and XRCC5 (Ku80) were proven to prob-
ably bind with SENP3, although only CUL3 had a marked
increase in cell lystates. CUL2 and Ku70 were tested as the
negative controls (Fig. 1F).
These data indicated an indispensible role of SENP3 in
regulating the SUMO2/3-targeted ubiquitination/degradation
on a global scale, in which the turnover of a number of
cancer-related nuclear proteins may be controlled.
SENP3 regulates the Sp1 protein level through
interfering with the SUMO2/3-targeted ubiquitin/
proteasome pathway
One of the molecules that well matched to all three aforemen-
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SENP3 with Sp1, we determined Sp1 mRNA and protein levels
in 293T cells where SENP3 was dose-increasingly overex-
pressed or knocked-down. Consistently, the protein level of Sp1
was increased by overexpression of SENP3 in a dose-depen-
dent manner. Knocking-down the SENP3 expression by siRNA
but not the control siRNA led to a robust decrease of the Sp1
protein (Fig. 2A, upper). The mRNA level of Sp1 was not
changed by overexpression or silencing of SENP3 (Fig. 2A,
bottom), indicating that the SENP3 promoted the stabilization of
Sp1 at post-transcription level, likely PTM level.
To conﬁrm the speculation that SENP3 and SUMO2/3 may
have the opposite effect on regulating Sp1 stability, we
transfected 293Tcells with SUMO3, and added cycloheximide
(CHX) to suppress the protein synthesis. Immunoblotting
results showed that the existed endogenous Sp1 protein was
at a lower level at each time point of CHX treatment in cells
overexpressing SUMO3, compared to the cells expressing
mock DNA (Fig. 2B, upper and bottom left) and its half-life
was apparently shorter in these cells (Fig. 2B, bottom right). In
addition, the endogenous Sp1 protein level declined along
with the dose of SUMO3, and this decline was attenuated in
the presence of proteasome inhibitor MG132 (Fig. 2C).
We next examined whether SENP3 physically interacted
with Sp1. Towards this end, 293T cells were transfected with
RH-SENP3, and endogenous Sp1 was detectable in the
immunoprecipitates. In parallel, when the antibody against
Sp1 pulled-down endogenous Sp1, the exogenous SENP3
was detectable in the immunoprecipitates (Fig. 2D). As
previously we showed that SENP3 protein accumulates
under oxidative stress, the cells were exposed to hydrogen
peroxide (H2O2) to induce an increase of endogenous
SENP3. The interaction of both proteins was further con-
ﬁrmed in their endogenous forms by co-immunoprecipitation
assay. In addition, an increase of Sp1 protein level and
increase of Sp1-SENP3 interaction were observed under the
H2O2 treatment when SENP3 was induced to accumulate to
some extent (Fig. 2E).
These results demonstrated that the turnover of Sp1
protein is regulated by SUMO3 through the ubiquitin/pro-
teasome pathway, and SENP3 up-regulates Sp1 protein
level likely through a physical interaction.
SENP3 catalyzes the de-conjugation of SUMO2/3 of Sp1
Sp1 was reported to undergo SUMO1 conjugation that was
displayed as a single band (Spengler and Brattain, 2006; Wang
et al., 2008). Thus we monitored the SUMO2/3 conjugation
pattern of Sp1 using a denaturing immunoprecipitation assay in



































Figure 3. SENP3 catalyzes the de-conjugation of SUMO2/3 of Sp1. (A–C) 293T cells were transfected with FLAG-Sp1, HA-
SUMO3, with or without SENP3 or mutant for 48 h, and treated with 10 μmol/L MG132 for the last 10 h. The SUMOylation of FLAG-
Sp1 was determined by co-IP using M2 beads and IB using the anti-HA and anti-Sp1 antibodies. RH-SUMO3 transfection was with a
concentration gradient in (B). RH-SENP3 and RH-SENP3 mutant C532A was co-transfected in (C).
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293T cells co-expressed with FLAG-Sp1 and HA-SUMO3 in
the presence of MG132. Exogenous Sp1 pulled-down by
FLAG displayed a smear-like SUMO3 conjugation pattern with
multiple bands mostly located at molecular weights higher than
130 kDa, conﬁrming that the SUMO3 conjugates of Sp1 were
one or multiple polySUMO chain(s) (Fig. 3A). These smear-like
multiple bands could be conﬁrmed as the speciﬁc SUMO3
conjugates of Sp1 because they were enhanced gradually in a
SUMO3 dose-dependent manner (Fig. 3B).
Next, we sought to verify that SUMO3-conjugated Sp1
was the substrate of SENP3. The SUMO3 pulled-down from
Sp1 was decreased by SENP3. The SENP3 C532A mutant
lacking the de-SUMOylation activity did not lead to the
decrease of SUMO3 conjugation (Fig. 3C). These results
demonstrated that Sp1 can be modiﬁed by SUMO3 and
SENP3 is a de-SUMOylating enzyme for Sp1 that removes
these conjugates.
SENP3 can regulate the ubiquitination of Sp1
by abrogating Sp1 interaction with RNF4
To explore the association of SUMO2/3 modiﬁcation and
degradation of Sp1, we transfected 293T cells with ubiquitin,
SUMO3 and Sp1, respectively or in combination, in the
presence of MG132. The denaturing co-IP assays showed
that the ubiquitin conjugates on Sp1 were readily
detectable when the cells were co-transfected with Ub and
SUMO3, but were signiﬁcantly decreased when the cells were
co-transfected with SENP3 in addition to Ub and SUMO3.
The SENP3 C532A mutant that lost de-SUMOylating activity
did not change the Ub conjugation of Sp1 (Fig. 4A).
We next examined the Sp1 level in the cells that were
transfected with SENP3 and a STUbL, RNF4. In the absence
of MG132, RNF4 apparently decreased the Sp1 protein level,
while SENP3 made Sp1 increase. In the presence of MG132,
RNF4 could no longer decrease the protein levels of Sp1
(Fig. 4B). These data indicated that SENP3 and RNF4 played
opposing roles in the event of ubiquitin/proteasome-mediated
degradation of Sp1. Because RNF4 has been shown to rec-
ognize SUMO1-conjugated Sp1 and mediate SUMO1-tar-
geted ubiquitination of Sp1 (Wang et al., 2008), we
constructed a SUMO3-Sp1 fusion protein. We found that in
cells overexpressing an increasing dose of RNF4, the
SUMO3-Sp1 fusion protein was gradually degraded (Fig. 4C,
upper), with a pattern similar to that of the endogenous wild-
type Sp1 (Fig. 4C, bottom). These data conﬁrmed that RNF4
does recognize the SUMO2/3 conjugates of Sp1 and serve as
a SUMO2/3-targeted ubiquitin E3 ligase for Sp1.
Next, we examined how SENP3 could antagonize the
RNF4-mediated Sp1 ubiquitination, and whether the
SENP3-mediated de-conjugation of SUMO2/3 from Sp1 led
to the disruption of the Sp1-RNF4 interaction. Co-IP was
conducted in cells that were transfected with FLAG-RNF4
and with SENP3-overexpressing or knocking-down plas-
mids. The Sp1-RNF4 binding was dramatically abrogated by
SENP3 overexpression, and in contrast, was facilitated in
the absence of SENP3 (Fig. 4D). The data veriﬁed that
SENP3 abrogates the interaction between RNF4 and Sp1,
which is apparently a consequence of the de-conjugation of
SUMO2/3 from Sp1. Taken together we suggest a mecha-
nism where SENP3 antagonized RNF4-mediated Sp1
ubiquitination and degradation, leading to upregulating of
Sp1 protein level (Fig. 4E).
The level of Sp1 displays an increase in parallel
with the level of SENP3 in gastric cancer cell lines
and specimens
Both SENP3 and Sp1 may over-accumulate in certain types
of human cancers (Honda et al., 2006; Kanai et al., 2006; Lou
et al., 2005). Therefore, we tested if the parallel association
between Sp1 and SENP3 levels in an in vitro cell system
reﬂects the situation in cancer cells and patient-derived tis-
sues. Screening several human gastric cancer cell lines, we
found that the MKN45 and MGC803 lines exhibit marked
differences in their SENP3 levels, and also had differences in
their Sp1 levels (Fig. 5A, left). Our previous study demon-
strated that the SENP3 protein was stabilized by reactive
oxygen species (ROS) (Huang et al., 2009); therefore, we
measured the ROS level in this pair of cell lines. Compared to
MGC803, MKN45 had higher ROS levels and expressed
more SENP3 and Sp1 proteins (Fig. 5A, right). The exposure
of cells to hydrogen peroxide (H2O2) for 0.5 h resulted in an
increase of the endogenous SENP3 protein level and a
simultaneous increase of the endogenous Sp1 protein level.
The antioxidant NAC could reverse the ROS-induced SENP3
increase and simultaneously block the Sp1 increase. These
effects of ROS-dependent SENP3 regulation remained true in
both cell types (Fig. 5B). Moreover, to directly test the role of
SENP3 in these lines, SENP3 level was interfered by
knockdown in MKN45 that had a higher basal SENP3 level,
and by overexpression in MGC803 that had a lower basal
SENP3 level. The results showed that when SENP3 was
overexpressed, the Sp1 level was increased; in contrast,
when SENP3 was knocked-down by siRNA, the ROS-in-
duced Sp1 increase was abolished (Fig. 5B). These results
strongly indicated a redox-dependent regulatory role of
SENP3 in Sp1 protein level in gastric cancer cells.
Furthermore, the SUMO2/3 and ubiquitin conjugations for
endogenous Sp1 were examined in MKN45 and MGC803
cells. Co-IP assays showed that MKN45 had lower levels of the
SUMO2/3 and ubiquitin conjugates for Sp1 than MGC803,
which linked to a higher SENP3 level and might explain a
higher Sp1 level in MKN45 cells (Fig. 5C). MKN45 cells with the
intact or silenced SENP3 were then exposed to H2O2 and
MG132 treatments. The results of co-IP indicated that SENP3
mediated H2O2-induced decreases of SUMO2/3 modiﬁcation
and ubiquitination of Sp1 in the endogenous condition (Fig. 5D).
To determine if the transcription activity of Sp1 was affec-
ted by SENP3, we measured mRNA levels of several target
SENP3 antagonizes SUMO2/3-targeted proteolysis RESEARCH ARTICLE
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genes of Sp1. VEGF, cyclin D and Bcl-2 were obviously
transcriptionally upregulated in SENP3 overexpression cells,
but these upregulations were almost completely prevented in
cells with SENP3 overexpression plus Sp1 knockdown. The
transcription of survivin was slightly affected (Fig. 5E).
We next explored whether the expression levels of
SENP3 correlated with the expression of Sp1 in human
gastric carcinoma specimens using immunohistochemistry
performed on the continuous sections of 21 surgically dis-
sected tissues derived from gastric cancer patients. The
positive immunohistochemical stain for Sp1 in the nuclei was
visible in the majority of cancerous epithelial cells. In parallel,
SENP3 stain was markedly positive in the same samples
and the same areas. Some tissues displayed a weaker Sp1
stain, whereas the SENP3 stain was also weaker in the
same areas (Fig. 5F, upper). The analysis of these paired
sections demonstrated a linear correlation between the
positive areas of both proteins in each specimen (Fig. 5F,
bottom left). In addition, the positive intensity of both proteins
in the same areas within one specimen displayed a linear
correlation (Fig. 5F, bottom right).
Finally, the correlation between SENP3 and Sp1 levels
was evaluated in the xenografts of human gastric cancers
grown in the nude mice. SGC7901 gastric cancer cells that
had moderate SENP3 level were stably transfected with
SENP3. The tumors in the stomachs in the SENP3 overex-
pression group were larger than those in the control (Fig. 5G,
upper). All lysates of the tumors were mixed in the same
group to compare the protein levels and ubiquitin conjugates
of Sp1 between two groups. IB showed that endogenous
Sp1 levels were higher in SENP3 overexpressed tumors.
Accordingly, the co-IP showed that endogenous ubiquitin
conjugates for Sp1 were less prominent in SENP3 overex-
pressing tumors (Fig. 5G, bottom). These results provided
evidence that SENP3 promotes the growth of gastric can-
cers, in which Sp1 protein level is increased by SENP3.
DISCUSSION
A quantitative proteomic study revealed a preference for
SUMO2-conjugated proteins being subsequently ubiquiti-
nated and degraded by the proteasome, in which ubiquitin
was found to accumulate in puriﬁed SUMO2 conjugates but
not in SUMO1 conjugates. In addition, endogenousSUMO2/3
conjugates, but not endogenous SUMO1 conjugates, were
found to accumulate in response to proteasome inhibitors
(Schimmel et al., 2008). The ﬁrst in vivo substrate identiﬁed for
the SUMO-targeted ubiquitination pathway was mammalian
PML, where SUMO2/3-targeted ubiquitination catalyzed by
RNF4 was required for PML degradation (Lallemand-Breit-
enbach et al., 2008). RNF4 was shown to act on substrates in
a SUMO2/3-dependent manner (Sriramachandran and Doh-
men, 2014). However, only SENP6 and no other SUMO2/3
speciﬁc SENPs has been reported to stabilize their substrates
(Mukhopadhyay et al., 2010). Our present study demon-
strated that SENP3 played a crucial regulatory role in RNF4-
mediated proteolysis that depended on the SUMO2/3-tar-
geted ubiquitination. Surprisingly, this regulation was seen on
a global scale; hundreds of proteins might be governed under
this regulation. Our previous study identiﬁed SENP3 as a
redox sensitive molecule that increased its abundance under
various conditions of oxidative stress (Huang et al., 2009).
Therefore, a profound change in global protein turnover could
be predicted following the increase of SENP3 under oxidative
stress-related physiological and pathological scenarios
including cancers.
Currently, it is unclear how SENPs acts on RNF4’s sub-
strates destined for the proteasome. When a SENP de-
SUMOylates these substrates, it has been assumed to do so
before or after the substrates’ arrival at the proteasome
(Hickey et al., 2012). In these cases, SENP might cooperate
with RNF4 to achieve the elimination of the SUMOylated
proteins. Alternatively, if de-SUMOylation occurred before
the addition of ubiquitin by RNF4, the SENP would antago-
nize RNF4, protecting the substrates from destruction.
Recent work by Mukhopadhyay et al. has demonstrated that
SENP6 stabilizes kinetochore component CENP-1 by
speciﬁcally shortening SUMO2/3 chains on CENP-1 and
antagonizing RNF4 (Mukhopadhyay et al., 2010). In the
present study, we show that SENP3 could remove all poly-
SUMO2/3 conjugates from Sp1 and from many other sub-
strates, and simultaneously remove ubiquitin conjugates.
Our data suggest that SENP3 can antagonize RNF4’s action
through a similar way that used by SENP6, but most likely
acts at a basic step, i.e., removes polySUMO chains at the
SUMO2/3 conjugate “roots”. In addition, we clearly
Figure 4. SENP3 can regulate the ubiquitination of Sp1 by
abrogating Sp1 interaction with RNF4. (A) 293T cells were
transfected with HA-ubiquitin (Ub), RH-SUMO3, FLAG-Sp1 and
RH-SENP3 or mutant for 48 h, and treated with 10 μmol/L
MG132 for the last 10 h. The Ubiquitination and SUMOylation of
FLAG-Sp1 were determined by co-IP using M2 beads and IB
using the anti-HA, anti-SUMO2/3 and anti-Sp1 antibodies.
(B) 293T cells were transfected with RNF4 and RH-SENP3 in
the presence/absence of MG132. Sp1 protein levels were
determined by IB using the antibody against Sp1. Sp1 levels
were quantiﬁed by intensity analysis and shown with relative
levels in the cells to those in the mock-transfected cells. *, P <
0.05. (C) 293T cells were transfected with SUMO3-Sp1 fusion
protein with dose-increased RNF in the presence/absence of
MG132. The protein levels of overexpressed (upper) Sp1 or
endogenous (bottom) were determined by IB using the antibody
against Sp1. (D) 293T cells and 293T cells stably expressing
non-speciﬁc shRNA (sh-NC) or SENP3 shRNA (sh-SENP3)
were transfected with SENP3 and FLAG-RNF4 respectively for
48 h. The Sp1 interactions with exogenous RNF4 were
determined by co-IP using anti-FLAG antibody and detected
by IB using the anti-Sp1 and anti-FLAG antibodies. (E) A model
we suggested to illustrate a role of SENP3 in antagonizing
RNF4-mediated ubiquitination/degradation of Sp1 and leading
to Sp1 stabilization.
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demonstrate that the SENP3-catalyzed de-conjugation of
SUMO2/3 from Sp1 prevents RNF4 from recognizing and
binding to Sp1. This conﬁrms the role of SENPs as antag-
onistic regulators for the substrates of RNF4 and provides
the biochemical evidence for a direct action of both SENP
and RNF4 with their common substrates.
The transcription factor Sp1 is important for the expres-
sion of thousands of housekeeping genes (Chang and Hung,
2012). Although Sp1 has been considered constitutively
activated in basal gene expression regulation, a variety of
PTMs and protein-protein interaction have been shown to
affect its activity and content, especially under speciﬁc cel-
lular processes (Wang et al., 2011).
Sp1 is subjected to several PTMs, which modulates the
protein level, the DNA-binding activity or the transactivation
potential of Sp1 (Chang and Hung, 2012). The PTMs
reported to date mainly include phosphorylation (Hung et al.,
2006; Tan and Khachigian, 2009), acetylation (Hung et al.,
2006; Waby et al., 2010), glycosylation (Han and Kudlow,
1997; Ozcan et al., 2010; Vij and Zeitlin, 2006), ubiquitination
(Wang et al., 2011), SUMOylation (Su et al., 1999; Wang
et al., 2008; Wang et al., 2011), ribosylation (Bouwman and
Philipsen, 2002) and oxidation (Sang et al., 2011). Confus-
ingly, evidence and conclusions are diverse and contradic-
tory for the PTM modulation of the Sp1 protein level. Kudlow
and colleagues provided early evidence that imply that
O-linked glycosylation protects Sp1 from proteolysis (Han
and Kudlow, 1997; Wells et al., 2001). In accordance with
these in vitro results, Spengler and Brattain demonstrated
in vivo data that a cAMP activator facilitates the production of
cleavage fragments. Their study identiﬁed Sp1 as a sub-
strate for SUMO1 modiﬁcation and showed an inverse
relationship between SUMO1-modiﬁed Sp1 and N-terminally
cleaved Sp1 (Spengler and Brattain, 2006). Subsequently,
they showed that phosphorylation mediates Sp1 de-
SUMOylation and destabilization during mitosis (Spengler
et al., 2008). Differently, Hung and colleagues showed that
phosphorylation shields Sp1 from the ubiquitin-dependent
degradation during mitosis (Chuang et al., 2008). This group
also found that modiﬁcation of Sp1 by SUMO1 at lysine 16
facilitates Sp1 degradation, and SUMOylation of Sp1 is
attenuated during tumorigenesis to increase Sp1 stability
(Wang et al., 2008). In addition, their subsequent studies
demonstrated that SUMO1 modiﬁcation of Sp1 could recruit
RNF4 as an ubiquitin E3 ligase that subjects SUMOy-
lated Sp1 to proteasomal degradation (Wang et al., 2011). A
recent study by Gong and colleagues demonstrated that
SUMO1 and SUMO2 exert opposing effects on Sp1 tran-
scriptional activity in the mouse lens system (Gong et al.,
2014). Therefore, there is no consistency in the relationship
between the SUMO modiﬁcation and protein stability of Sp1.
In the present study, we used approaches of co-overex-
pressing and silencing SUMO3, ubiquitin and/or SENP3 to
verify the relationship between SUMO modiﬁcation and the
protein stability of Sp1. The results clearly demonstrated that
SUMO2/3 conjugations facilitated Sp1 degradation through
the formation of SUMO2/3-targeted ubiquitination, whereas
SENP3, a SUMO2/3-speciﬁc protease, stabilized Sp1 via
blockage of SUMO-targeted ubiquitination and proteasome-
mediated degradation. The importance of the role of SENP3
in Sp1 regulation can be highlighted in two aspects. First,
STUbL RNF4 has preference for substrates conjugated with
SUMO2/3 that form SUMO chains more effectively than
SUMO1 (Matic et al., 2008). Therefore, it is critical to know
whether the SUMO2/3 speciﬁc SENP(s) naturally play an
antagonistic role for RNF4. Our data have shown that SENP3
regulates the Sp1 protein level through the removal of the
polySUMO2/3 chains, thus blocking the recognition and
binding by RNF4. Second, the protein level of Sp1 must be
Figure 5. The level of Sp1 displays an increase in parallel
with the level of SENP3 in gastric cancer cell lines and
specimens. (A) The protein levels of SENP3 and Sp1 were
determined by IB and ROS levels were detected by ﬂow
cytometry using the ﬂuorogenic probe DCFH-DA in gastric
cancer cell lines MKN45 and MGC803. (B) MKN45 cells were
transfected with non-speciﬁc siRNA or SENP3 siRNA for 72 h.
MGC803 cells were transfected with RH-SENP3 for 48 h. The
cells were pre-treated with 5 mmol/L NAC for 4 h and 200 μmol/
L H2O2 for an additional 0.5 h. SENP3 and Sp1 protein levels
were determined by IB. (C) The ubiquitin and SUMO2/3
conjugations for endogenous Sp1 were determined by co-IP
in MKN45 and MGC803 cells in the presence of 10 μmol/L
MG132. 1 = MKN45 cells; 2 = MGC803 cells. (D) MKN45 cells
stably expressing non-speciﬁc shRNA (sh-NC) or SENP3
shRNA (sh-SENP3) were exposed to 200 μmol/L H2O2 in the
presence of 10 μmol/L MG132. The SUMO2/3 and ubiquitin
conjugations for endogenous Sp1 were examined by co-IP. 1 =
sh-NC; 2 = sh-SENP3. (E) MGC803 cells stably expressing
non-speciﬁc shRNA (sh-NC) or Sp1 shRNA (sh-Sp1) were
transiently transfected with GFP-SENP3 or mock for 48 h. The
levels of mRNA of Sp1 target genes, VEGF, Cyclin D1, Bcl-2
and Survivin, were monitored by qRT-PCR. The data repre-
sented with mean ± SD from two assays and three replicates in
every assay. *, P < 0.05. (F) Immunohistochemistry for SENP3
and Sp1 was performed in serial sections derived from different
gastric cancer specimens (#1, #2 = two random specimens).
The brown staining represents a positive signal. Bar = 30 µm.
Image analysis was performed in the paired sections and the
percentages of positive areas of both proteins in each specimen
were displayed (specimens n = 25) (bottom left). The intensities
of both proteins in the same areas within one specimen were
displayed (ﬁeld n = 50) (bottom right). (G) Human gastric cancer
cell line SGC7901 cells stably overexpressing SENP3 or vector
were inoculated into nude mice to form tumor xenografts, and
the tumors were then recovered, minced into small pieces and
implant beneath the serosa of the stomach of other mice to
grow for eight weeks (upper). All lysates of the tumors in the
same group were mixed. The protein levels and ubiquitin
conjugations of endogenous Sp1 were evaluated by co-IP and
IB using the indicated antibodies. 1 = mock DNA-expressing
tumor lysates; 2 = SENP3-overexpressing tumor lysates
(bottom).
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controlled by a plethora of regulatory mechanisms and may
ﬂuctuate along with the physiological or pathological condi-
tions. Which SENP(s) would prevail in the regulation of Sp1
under a given condition depends on the level and enzymatic
activity of the SENPs under that condition. Our previous
studies have demonstrated that the SENP3 rapidly (within 1
h) increases its own level through a redox-sensitive stabi-
lization under oxidative stress conditions (Huang et al., 2009;
Yan et al., 2010) and remains accumulated in many types of
human cancer tissues (Han et al., 2010; Yan et al., 2010).
Comparatively, no other SENPs are known to be consistently
upregulated under stress or cancer-prone conditions. In the
present study, we have shown that H2O2 treatment leads to
an increase of Sp1 in the gastric cancer cell line, which is
dependent on an induction of SENP3. Therefore, the SENP3
regulation of the Sp1 level may explain that Sp1 is increased
under stress conditions and in cancerous tissues.
The overexpression of Sp1 is considered a prognostic
indicator for the poor survival of gastric cancer patients
(Wang et al., 2003; Yao et al., 2004). A study based on 396
gastric tissue samples conﬁrmed that the expression of Sp1
increases with tumor progression (Lee et al., 2013). A
number of microRNA molecules were recently suggested to
regulate Sp1 at a post-transcription level (Guo et al., 2013;
Liu et al., 2013). However, the mechanisms underlying Sp1
overexpression have not been adequately investigated. We
herein show a close correlation between the protein levels of
SENP3 and Sp1 in the patient’s gastric specimens, as well
as in the nude mouse xenografts of human gastric cancers.
Together with the biochemical and molecular biological data
generated in cultured cells, these results have provided a
novel regulatory mechanism to explain the overexpression of
Sp1 in gastric cancers at the post-translation level.
MATERIALS AND METHODS
Cell culture and treatments
Gastric carcinoma cell lines SGC-7901, MKN45 and MGC803 cells
were cultured in RPMI 1640 medium (HyClone). The HEK293T
(293T) cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(HyClone). All media were supplemented with 10% newborn calf
serum. The cells were maintained at 37°C in a humidiﬁed atmo-
sphere with 5% CO2. The stable cell lines with SENP3 over-ex-
pression were used in the previous work (Ren et al., 2014). To
establish the stable MGC803 cell lines bearing Sp1 shRNA (sh-Sp1)
or non-speciﬁc shRNA (sh-NC), ZsGreen1 co-expressing lentiviral
expression vectors were transiently transfected into 293FT cells.
After 72 h, the supernatants were harvested to infect MGC803 cells
with a ﬁnal concentration of 10 μg/mL polybrene. Lastly, the
ZsGreen1-positive cells were sorted on a FACSAria II ﬂow cytometer
(BD Biosciences). The nucleotide sequence in shRNAs against Sp1
was: CCGGCCCAAGTTTATTTCTCTCTTACTCGAGTAAGAGAGA
A ATAAACTTGGGTTTTT. The MGC803 cells stably expressing
sh-NC or sh-Sp1 were transiently transfected with GFP-SENP3 or
mock for 48 h to reach the effects of SENP3 overexpression with
Sp1 knockdown simultaneously.
MG132 (Merck) was used to block proteasome activity. When
needed, the anti-oxidant N-acetyl-L-cysteine (NAC) (Sigma-Aldrich)
was pre-administered for 4 h before other treatments.
Immunoblotting (IB)
Cells or tissues were lysed. The proteins were separated on 8% or
10% SDS-PAGE gels, and then were transferred to nitrocellulose
membranes before determined by the antibodies. The methods were
as previously used (Yan et al., 2010).
Co-immunoprecipitation (co-IP)
Denaturing co-IP was performed to detect the SUMO or ubiquitin
conjugations of Sp1. Cells were lysed in 150 μL of the denaturing
buffer (50 mmol/L Tris (pH 7.4), 1% SDS) for 30 min. After boiling for
10 min, cell lysates were centrifuged for 15 min at room temperature.
Supernatants were mixed with IP buffer (50 mmol/L Tris (pH 7.4),
150 mmol/L NaCl, 1 mmol/L EDTA, 1% Triton X-100) and incubated
with speciﬁc antibodies as indicated. The proteins were separated
from the beads using IB loading buffer, then the supernatants were
collected for IB. The routine co-IP was carried out using methods
described in our previous studies (Huang et al., 2009).
Antibodies
The following antibodies were used in this study: mouse monoclonal
antibodies against β-actin (Sigma); Rabbit polyclonal antibodies
against Sp1 (Santa Cruz Biotechnology); mouse monoclonal [Ubi-1]
antibodies against Ubiquitin (Abcam), the rabbit polyclonal antibod-
ies against HA (Abcam), the mouse monoclonal antibodies against
GFP (Abcam), mouse anti-RH (Qiagen), the mouse monoclonal
antibodies against FLAG (sigma), the rabbit monoclonal antibodies
against SUMO2/3 (Cell Signaling Technology), normal rabbit IgG
(CST), the rabbit polyclonal antibodies against RNF4 (Abgent), and
the rabbit polyclonal antibodies against SENP3 (Protein Techgroup).
Mass spectrometry
After gel pieces were destained and washed, the spots were incu-
bated in 0.2 mol/L NH4HCO3 for 20 min and then lyophilized. The in-
gel proteins were reduced with dithiothreitol (10 mmol/L DTT/ 100
mmol/L NH4HCO3) for 30 min at 56°C, then alkylated with iodoac-
etamide (50 mmol/L IAA/100 mmol/L NH4HCO3) in the dark at room
temperature for 30 min before brieﬂy rinsed and digested overnight
in 12.5 ng/mL trypsin in 25mmol/L NH4HCO3. The peptides were
extracted three times with 60% ACN/0.1% TFA. The extracts were
pooled and dried completely by a vacuum centrifuge. Experiments
were performed on a Q Exactive mass spectrometer that was cou-
pled to Easy nLC (Thermo Fisher Scientiﬁc). Data were acquired
using a data-dependent top10 method dynamically choosing the
most abundant precursor ions from the survey scan (300–1800 m/z)
for HCD fragmentation. Survey scans were acquired at a resolution
of 70,000 at m/z 200 and resolution for HCD spectra was set to
17,500 at m/z 200. MS/MS spectra were searched using MASCOT
engine (Matrix Science, London, UK; version 2.2). Each sample was
repeated twice.
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The plasmid FLAG-Sp1 was constructed by inserting an Sp1 frag-
ment ampliﬁed from pcDNA-Sp1 into NotI-XbalI sites in the pcDNA-
FLAG vector. The PCR-ampliﬁed SUMO3 fragment with EcoRI and
NotI restriction sites from HA-SUMO3 was ligated into FLAG-Sp1 to
obtain the FLAG-SUMO3-Sp1 fusion protein. The plasmid FLAG-
RNF4 was made by PCR using speciﬁc primers from plasmid RNF4
and by subcloning the PCR products into BamHI and NotI restriction
sites of the pcDNA-FLAG vector. The pEGFP-C1-SENP3 and its
mutant constructs have been previously described (Yan et al., 2010).
The siRNA speciﬁc for SENP3 and non-speciﬁc control siRNA
oligonucleotides were synthesized and used as previously (Han
et al., 2010).
Reactive oxygen species (ROS) detection
DCFH-DA (2-dichlorodihydroﬂuorescein diacetate; Sigma) was used
as a ROS-capturing reagent according to the previous method (Cai
et al., 2008).
Real-time quantitative PCR (RT-qPCR)
The total RNA was isolated following the guide of the TRIzol reagent
kit (Invitrogen, Carlsbad, CA). The cDNA synthesis was performed
on 2 μg of the total RNA with a reverse transcription kit (Promega,
Madison, WI). Real-time PCR was conducted on the ABI Prism 7500
system using SYBR Green (Roche Applied Science, Mannheim,
Germany) and following the manufacturer’s instructions.
The primers used were listed below.











Mouse model for orthotopic gastric cancer development
The SGC7901 cells of 1 × 107 were injected subcutaneously into the
6-wk-old Balb/c nu-nu mice. Two weeks later, tumors were har-
vested and minced into small pieces (1 mm3) in RPMI-1640 basal
medium. Each tumor piece was placed into a small tissue pocket
formed in the middle wall of the greater curvature of the stomach
beneath the serosa in another nude mouse, and ﬁxed using a purse
string suture with 7-0 absorbable sutures. After tumor implantation,
the stomach was relocated into the abdominal cavity followed by
abdominal closure (Li et al., 2011) and tumors were allowed to grow
for 8 weeks. All procedures were performed under anesthesia with
ketamine (50 mg/kg)/midazolam (10 mg/kg) following an approved
protocol in conformity with institutional guidelines for the care and
use of laboratory animals in Shanghai Jiao Tong University School of
Medicine.
Immunohistochemistry
The paraformaldehyde-ﬁxed and parafﬁn-embedded sections of
human gastric cancer specimens were archived pathologic speci-
mens from the Ren Ji Hospitals and obtained following an institute-
approved protocol. The immunohistochemistry for the SENP3 and
Sp1 was conducted on the continuous sections using a previous
method (Cai et al., 2008). The ratio of the positive area for SENP3
and Sp1 was quantiﬁed by the Zeiss KS400 software. The
mean optical density of 50 ﬁelds of the same size from 3 pairs of
pathologic specimens expressing SENP3 and Sp1 stained by im-
munohistochemistry was detected.
Statistical analysis
Results presented were derived from at least three independent
experiments. All statistical analyses were performed by using the
SPSS software package. The relationship between the expression of
SENP3 and Sp1 were examined by the Spearman rank correlation
coefﬁcient. A P-value of <0.05 was considered statistically signiﬁcant.
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